XPOVIO® Approved in Taiwan for the Treatment of RRMM and DLBCL
“Antengene is very pleased to receive regulatory approval for XPOVIO® in Taiwan for R/R MM and R/R DLBCL. There remains an unmet need to extend survival for patients with these life-threatening diseases and XPOVIO® presents Taiwan physicians and patients with a new novel addition to existing therapies. We continue to build our Antengene presence across APAC markets and in Taiwan. We also look forward to introducing XPOVIO® and securing reimbursement in order to extend access to this first in class therapy for our physicians and patients.”said Thomas Karalis, Antengene’s Corporate Vice President, Head of Asia Pacific Region.
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
